-
在DTC的治疗管理中,甲状腺全切除术(total thyroidectomy, TT)或甲状腺近全切除术(near total thyroidectomy, NTT)是清除肿瘤组织的主要方法。术后131I治疗虽然提高了高危患者的无病生存率和总生存率,但对中低危患者的生存率提高似乎没有明显作用[1-2]。对于术后行131I治疗的DTC患者来说,选择最佳剂量的131I以达到成功治疗的目的仍存在挑战。2项大型Ⅲ期临床试验的长期随访结果证明,低剂量(1.1 GBq)和高剂量(3.7 GBq)131I对低危或中低危DTC患者的短期疗效及长期预后差异均无统计学意义[3-4]。但是在另一项大型随机对照试验(randomized controlled trial, RCT)中,相较于低剂量(1.1 GBq)131I治疗,高剂量(3.7 GBq)131I治疗更易实现短期治疗成功的目标[5]。本研究旨在对已发表的相关文献进行Meta分析,以期对不同剂量131I治疗中低危DTC患者后的短期疗效及长期预后进行评价。
-
从各数据库中检索到了4885篇文献,筛除重复文献后获得2701篇,其中2653篇因摘要或文题与研究主题不相关被排除。经全文审查后,又有41篇文献被剔除。最后筛选出7篇RCT文献,共2754例患者。文献筛选流程图见图1。纳入的RCT文献特征见表1。
图 1 不同剂量131I治疗中低危分化型甲状腺癌后短期疗效及长期预后Meta分析的文献纳入流程图
Figure 1. Flow chart for literature inclusion process for Meta-analysis of short-term efficacy and long-term prognosis of different doses of 131I in the treatment of low- and intermediate-risk differentiated thyroid cancer
纳入文献 发表
年份国家 例数
(女/男)病理类型(PTC/FTC) TNM分期 手术术式 治疗前TSH
刺激方式治疗剂量分组 平均随访
时间(月)治疗后短期成功标准 复发标准 Dehbi等[3] 2019 英国 326/108 − T1~3,
N1~3,
M0TT或NTT(伴或不伴淋巴结清扫术) THW或外源性补充rhTSH 低剂量组(1.1 GBq):217例;
高剂量组(3.7 GBq):217例78 治疗后6~9个月:WBS(−); sTg<2 ng/ml 影像检查(WBS、超声、PET/CT等)提示复发;组织病理学检查结果证实为复发;sTg≥2 ng/ml Schlumberger
等[4]2018 法国 590/162 693/58 T1~3,
N0,
M0TT THW或外源性补充rhTSH 低剂量组(1.1 GBq):363例;
高剂量组(3.7 GBq):363例6~110 治疗后6~10个月:超声(−)且sTg<1 ng/ml;TgAb(+),WBS(−) 组织病理学检查结果证实为复发;影像检查提示复发;sTg>1 ng/ml Fallahi等[5] 2012 伊朗 286/55 326/15 T1~3,
N1~3,
M0TT(大多数伴淋巴结清扫术) THW 低剂量组(1.1 GBq):171例;
高剂量组(3.7 GBq):170例12 治疗后6~12个月:WBS(−);sTg<2 ng/ml WBS(+);sTg>2 ng/ml Kukulska等[7] 2010 波兰 285/24 265/44 T1~3,
N1~3,
M0TT或NTT(大多数伴淋巴结清扫术) THW 低剂量组(1.1 GBq或2.2 GBq):214例;高剂量组(3.7 GBq):95例 24~120 治疗后12个月:WBS(−);sTg<10 ng/ml sTg>1 ng/ml;超声或其他影像检查提示复发 Ma等[8] 2017 中国 199/79 268/7a T1~3,
N1~3,
M0TT 或NTT(伴或不伴淋巴结清扫术) THW 低剂量组(1.85 GBq):155例;高剂量组(3.7 GBq):123例 24~36 治疗后6~9个月:WBS(−);sTg<2 ng/ml 影像检查(WBS、超声等)提示复发;sTg>2 ng/ml Ahtiainen等[9] 2020 芬兰 129/31 146/11b T1~3,
N1~3,
M0TT或NTT THW 低剂量组(1.1 GBq):81例、
高剂量组(3.7 GBq):79例156 治疗后4~8个月:WBS(−);sTg<1 ng/ml 组织病理学检查结果证实为复发;影像检查(WBS、CT、MRI等)提示复发;sTg>1 ng/ml Dong等[10] 2021 中国 363/143 − T1~2,
N0~1,
M0TT或NTT(伴或不伴淋巴结清扫术) THW 低剂量组(1.1 GBq):251例;
高剂量组(3.7 GBq):255 例54 治疗后6~9个月:超声(−)且sTg<1 ng/ml或抑制性Tg<0.2 ng/ml;TgAb(+);WBS(−) 组织病理学检查结果证实为复发;影像检查(超声、CT等)提示复发;sTg>1 ng/ml 注:a表示另有3例为滤泡型甲状腺乳头状癌;b表示另有3例为PTC和FTC均有;−表示无此项数据;PTC为甲状腺乳头状癌;FTC为甲状腺滤泡状癌;TNM为肿瘤、淋巴结、转移;TSH为促甲状腺激素;TT为全切除术;NTT为近全切除术;THW为甲状腺激素戒断;rhTSH为重组人促甲状腺激素;WBS为全身扫描;sTg为刺激性甲状腺球蛋白;PET为正电子发射断层显像术;CT为计算机体层摄影术;TgAb为甲状腺球蛋白抗体;MRI为磁共振成像 表 1 纳入的7篇不同剂量131I治疗中低危分化型甲状腺癌后短期疗效及长期预后的研究文献的基本特征
Table 1. Basic characteristics of 7 included studies on short-term efficacy and long-term prognosis of different doses of 131I in the treatment of low- and intermediate-risk differentiated thyroid cancer
-
参考Jadad量表,纳入的7篇文献中,1篇(文献[7])得分为2分,5篇(文献[3、4、8、9、10])得分为3分,1篇(文献[5])得分为5分。所有文献(100%,7/7)均描述了随机分配方案,大部分文献(71.4%,5/7)描述了分配隐藏方法,但对实施者与参与者(14.3%,1/7)、结果评价(57.1%,4/7)采用盲法试验的文献占比相对较低。总体而言,纳入文献的方法学质量比较好,偏倚风险相对较低。纳入文献的偏倚风险见图2。
-
对7项研究的异质性分析结果显示,差异有统计学意义(P=0.002,I2=72%),故采用随机效应模型。低剂量组和高剂量组131I治疗后短期疗效的差异无统计学意义(RR=0.93,95%CI:0.86~1.01,P=0.07)(图3)。敏感性分析结果显示,当剔除文献[5]时,其余6项研究的异质性的差异无统计学意义(P=0.87,I2=0%),采用固定效应模型分析得出低剂量组和高剂量组131I治疗后短期疗效的差异仍无统计学意义(RR=0.97,95%CI:0.93~1.02,P=0.19)(图4)。仅从短期疗效来看,倾向于高剂量131I的清甲成功率高于低剂量131I (72.1%对68.6%;剔除文献[5]后为73.4%对72.7%),但Meta分析结果显示,不同131I治疗剂量组间的短期疗效的差异无统计学意义(图4)。
图 3 不同剂量131I治疗中低危分化型甲状腺癌后短期疗效的森林图
Figure 3. Forest plot of short-term efficacy after different doses of 131I in the treatment of low- and intermediate-risk differentiated thyroid cancer
图 4 不同剂量131I治疗中低危分化型甲状腺癌后短期疗效的森林图(敏感性分析)
Figure 4. Forest plot of short-term efficacy after different doses of 131I in the treatment of low- and intermediate-risk differentiated thyroid cancer (sensitivity analysis)
本研究对地区、术式、危险度分层、治疗前TSH刺激方式及清甲成功定义标准甲状腺球蛋白(thyroglobulin,Tg)水平等方面进行了亚组分析。根据纳入研究中131I治疗前TSH刺激方式的不同,将纳入研究分为甲状腺激素戒断(thyroid hormone withdrawal,THW)和外源性补充重组人促甲状腺激素(recombinant human thyroid stimulating hormone,rhTSH)2个亚组。1项研究中将Tg标准分为刺激性Tg(stimulated Tg,sTg)<1 ng/ml或抑制性Tg<0.2 ng/ml,故将其剔除后分析。其余6项研究的Meta分析结果显示,地区、术式、危险度分层、治疗前TSH刺激方式及Tg水平各亚组间的差异均无统计学意义(表2)。各亚组异质性分析结果显示,亚洲组、TT组、中低危组、THW组以及Tg<2 ng/ml组间存在异质性,采用随机效应模型;将文献[5]剔除后采用固定效应模型进行分析,结果同前。
亚组组别 文献序号 RR(95%CI) P值 异质性检验 P值 I2(%) 地区 欧洲 3–4,7,9 0.95(0.90,1.01) 0.08 0.98 0 亚洲 5,8,10 0.86(0.68,1.08) 0.20 <0.0001 92 术式 TT 4–5 0.78(0.49,1.23) 0.28 0.0007 91 NTT 3,7–10 0.97(0.93,1.01) 0.15 0.76 0 危险度分层 中低危 3,5,7–10 0.92(0.83,1.01) 0.08 0.0004 78 低危 4 0.98(0.83,1.14) 0.76 − − TSH刺激方式 THW 5,7–10 0.90(0.79,1.02) 0.11 0.0001 83 THW/外源性补充rhTSH 3–4 0.96(0.90,1.03) 0.23 0.79 0 短期疗效评估标准 Tg<10 ng/ml 7 0.94(0.86,1.03) 0.20 − − Tg<2 ng/ml 3,5,8 0.85(0.68,1.05) 0.13 0.0001 90 Tg<1 ng/ml 4,9 0.96(0.84,1.11) 0.61 0.77 0 注:文献[10]因将短期疗效评估标准Tg分为刺激性Tg<1 ng/ml或抑制性Tg<0.2 ng/ml,故将其剔除。TT为全切除术;NTT为近全切除术;TSH为促甲状腺激素;THW为甲状腺激素戒断;rhTSH为重组人促甲状腺激素;Tg为甲状腺球蛋白;RR为相对危险度;CI为置信区间;−表示无此项数据 表 2 不同剂量131I治疗中低危分化型甲状腺癌后短期疗效的亚组分析
Table 2. Subgroup analysis of short-term efficacy of different doses of 131I in the treatment of low- and intermediate-risk differentiated thyroid cancer
-
纳入的7项研究均描述了复发数据。对7项研究行Meta分析未显示异质性(P=0.78,I2=0%),采用固定效应模型。Meta分析结果显示,低剂量组和高剂量组131I治疗对中低危DTC患者的长期预后的差异无统计学意义(RR=0.93,95%CI:0.58~1.49,P=0.77)(图5)。7项研究中有5项研究描述了后续治疗的数据,其中有4项研究提供了后续进一步131I治疗的数据,另有1项研究对后续131I治疗的数据报道模糊,故采用该研究的前期数据进行Meta分析,结果表明,低剂量组和高剂量组后续131I治疗的差异有统计学意义,接受低剂量131I治疗的患者更有可能因残留甲状腺或持续性/复发性疾病接受2次甚至多次治疗 (RR=1.61,95%CI:1.33~1.95,P<0.001)(图6)。
图 5 不同剂量131I治疗中低危分化型甲状腺癌后长期预后的森林图
Figure 5. Forest plot of long-term prognosis after different doses of 131I in the treatment of low- and intermediate-risk differentiated thyroid cancer
图 6 不同剂量131I治疗中低危分化型甲状腺癌后后续131I治疗的森林图
Figure 6. Forest plot of subsequent 131I treatment after different doses of 131I treatment for low- and intermediate-risk differentiated thyroid cancer
我们对术式、危险度分层及随访时间等进行了亚组分析,结果显示,随访时间为5年及5年以上的患者的复发率与随访时间低于5年的患者的复发率的差异无统计学意义。我们将随访时间延长至10年再次行亚组分析,结果无明显变化。Meta分析结果显示,不同剂量131I治疗中低危DTC后各亚组间的长期预后的差异均无统计学意义(表3)。
亚组组别 文献序号 RR(95%CI) P值 异质性检验 P值 I2(%) 术式 TT 4–5 1.09(0.28,4.21) 0.80 0.21 36 NTT 3,7–10 0.88(0.52,1.50) 0.63 0.87 0 危险度分层 中低危 3,5,7–10 2.00(0.50,7.94) 0.32 − − 低危 4 0.83(0.50,1.37) 0.46 0.89 0 随访时间1 <5 年 5,8,10 0.45(0.10,2.02) 0.30 0.84 0 ≥5年 3–4,7,9 1.03(0.60,1.75) 0.93 0.69 0 随访时间2 <10 年 3–5,7–8,10 1.00(0.56,1.76) 0.99 0.68 0 ≥10年 9 0.80(0.35,1.82) 0.54 − − 注:TT为全切除术;NTT为近全切除术;RR为相对危险度;CI为置信区间;−表示无此项数据 表 3 不同剂量131I治疗中低危分化型甲状腺癌后长期预后的亚组分析
Table 3. Subgroup analysis of long-term prognosis after different doses of 131I in the treatment of low- and intermediate-risk differentiated thyroid cancer
不同剂量131I治疗中低危分化型甲状腺癌的短期疗效及长期预后的Meta分析
Efficacy and prognosis after different doses of 131I treatment for differentiated thyroid cancer in low- and intermediate-risk patients: a Meta-analysis
-
摘要:
目的 评价中低危分化型甲状腺癌(DTC)患者不同剂量131I治疗后的短期疗效及长期预后的差异。 方法 检索 PubMed、EMBASE、Cochrane Library、中国知网、万方数据库等数据库中关于DTC患者131I治疗后短期疗效及长期预后评估的文献,检索时间均为自建库至2022年9月。根据纳入和排除标准筛选文献。应用RevMan 5.4软件进行Meta分析。采用相对危险度( RR)及其 95%置信区间(CI)对二分类数据进行效应统计量描述。采用χ2检验和I2值对文献进行异质性评价。 结果 最终纳入7篇文献,共2754例患者,其中低剂量组(1.1~2.2 GBq)1452例、高剂量组(3.7 GBq)1302例。(1)低剂量组和高剂量组131I治疗后短期疗效的差异无统计学意义(RR=0.93,95%CI:0.86~1.01,P=0.07)。对地区[欧洲(RR=0.95,95%CI:0.90~1.01,P=0.08);亚洲(RR=0.86,95%CI:0.68~1.08,P=0.20)]、术式[甲状腺全切除术(TT)(RR=0.78,95%CI:0.49~1.23,P=0.28);甲状腺近全切除术(NTT) (RR=0.97,95%CI:0.93~1.01,P=0.15)]、危险度分层[中低危(RR=0.92,95%CI:0.83~1.01,P=0.08);低危(RR=0.98,95%CI:0.83~1.14,P=0.76)]、治疗前TSH刺激方式[甲状腺激素戒断(THW)(RR=0.90,95%CI:0.79~1.02,P=0.11);THW/外源性补充重组人促甲状腺激素(RR=0.96,95%CI:0.90~1.03,P=0.23)]及清甲成功定义标准甲状腺球蛋白(Tg)水平[Tg<10 ng/ml(RR=0.94,95%CI:0.86~1.03,P=0.20);Tg<2 ng/ml(RR=0.85,95%CI:0.68~1.05,P=0.13); Tg<1 ng/ml(RR=0.96,95%CI:0.84~1.11,P=0.61)]等做进一步分析,结果显示,各亚组间的差异均无统计学意义。(2)低剂量组和高剂量组131I治疗后长期预后的差异无统计学意义(RR=0.93,95%CI:0.58~1.49,P=0.77)。对术式[TT(RR=1.09,95%CI:0.28~4.21,P=0.80);NTT(RR=0.88,95%CI:0.52~1.50,P=0.63)]、危险度分层[中低危(RR=2.00,95%CI:0.50~7.94,P=0.32);低危(RR=0.83,95%CI:0.50~1.37,P=0.46)]及随访时间{[<5年(RR=0.45,95%CI:0.10~2.02,P=0.30);≥5年(RR=1.03,95%CI:0.60~1.75,P=0.93)] 、[<10年(RR=1.00,95%CI:0.56~1.76,P=0.99);≥10年(RR=0.80,95%CI:0.35~1.82,P=0.54)]}的进一步分析结果显示,各亚组间的差异均无统计学意义。(3)低剂量组和高剂量组后续131I治疗的差异有统计学意义(RR=1.61,95%CI:1.33~1.95,P<0.001)。 结论 低剂量和高剂量131I治疗中低危DTC后的短期疗效及长期预后的差异均无统计学意义;低剂量131I治疗的患者更有可能因为残留甲状腺或持续性/复发性疾病而进行≥ 2次的131I治疗。 Abstract:Objective To evaluate the short-term efficacy and long-term prognosis of patients with low- and intermediate-risk differentiated thyroid cancer (DTC) treated with different 131I doses. Methods Studies on the short-term efficacy and long-term prognosis evaluation of patients with DTC after 131I treatment were searched from databases such as PubMed, EMBASE, Cochrane Library, CNKI, and Wanfang from inception to September 2022. Screening of literature was based on specific inclusion and exclusion criteria. Meta-analysis was performed with RevMan 5.4 software. Dichotomous data were compared using relative risk (RR), and 95% confidence intervals (95%CI) were calculated for each estimate. Heterogeneity was evaluated by χ2 test and I2 value. Results Seven studies with 2754 patients were included. The low-dose group (1.1–2.2 GBq) comprised 1452 cases, and the high-dose group (3.7 GBq) consisted of 1302 cases. (1) No significant difference in short-term efficacy (RR=0.93, 95%CI: 0.86–1.01, P=0.07) was found between the low- and high-dose groups. Further analysis showed no statistically significant difference between the subgroups of regions (Europe (RR=0.95, 95%CI: 0.90–1.01, P=0.08) and Asia (RR=0.86, 95%CI: 0.68–1.08, P=0.20)); operation modes(total thyroidectomy (RR=0.78, 95%CI: 0.49–1.23, P=0.28); and near total thyroidectomy (RR=0.97, 95%CI: 0.93–1.01, P=0.15)); risk stratification (low and intermediate risk (RR=0.92, 95%CI: 0.83–1.01, P=0.08); and low risk (RR=0.98, 95%CI: 0.83–1.14, P=0.76)); thyroid-stimulating hormone (TSH) stimulation modes (thyroid hormone withdrawal (RR=0.90, 95%CI: 0.79–1.02, P=0.11); and thyroid hormone withdrawal/recombinant human TSH (RR=0.96, 95%CI: 0.90–1.03, P=0.23)); and criteria for successful ablation (Tg<10 ng/ml (RR=0.94, 95%CI: 0.86–1.03, P=0.20), Tg<2 ng/ml (RR=0.85, 95%CI: 0.68–1.05, P=0.13), and Tg<1 ng/ml (RR=0.96, 95%CI: 0.84–1.11, P=0.61)). (2)No significant difference in long-term prognosis was observed between the low- and high-dose groups (RR=0.93, 95%CI: 0.58–1.49, P=0.77). Further analysis showed no statistically significant difference between the subgroups of operation modes (total thyroidectomy (RR=1.09, 95%CI: 0.28–4.21, P=0.80); and near total thyroidectomy (RR=0.88, 95%CI: 0.52–1.50, P=0.63)); risk stratification (low and intermediate risk (RR=2.00, 95%CI: 0.50–7.94, P=0.32); and low risk (RR=0.83, 95%CI: 0.50–1.37, P=0.46)); and follow-up time (<5 years (RR=0.45, 95%CI: 0.10–2.02, P=0.30), ≥5 years (RR=1.03, 95%CI: 0.60–1.75, P=0.93), <10 years (RR=1.00, 95%CI: 0.56–1.76, P=0.99), and ≥10 years (RR=0.80, 95%CI: 0.35–1.82, P=0.54)). (3) Significant difference in subsequent 131I treatment was found between the low- and high-dose groups (RR=1.61, 95%CI: 1.33–1.95, P<0.001). Conclusions No statistically significant difference in short-term efficacy and long-term prognosis was observed between low- and high-dose 131I treatments for low- and intermediate-risk DTC. Patients treated with low-dose 131I are likely to undergo ≥ 2 times of 131I treatment due to residual thyroid or persistent/recurrent diseases. -
表 1 纳入的7篇不同剂量131I治疗中低危分化型甲状腺癌后短期疗效及长期预后的研究文献的基本特征
Table 1. Basic characteristics of 7 included studies on short-term efficacy and long-term prognosis of different doses of 131I in the treatment of low- and intermediate-risk differentiated thyroid cancer
纳入文献 发表
年份国家 例数
(女/男)病理类型(PTC/FTC) TNM分期 手术术式 治疗前TSH
刺激方式治疗剂量分组 平均随访
时间(月)治疗后短期成功标准 复发标准 Dehbi等[3] 2019 英国 326/108 − T1~3,
N1~3,
M0TT或NTT(伴或不伴淋巴结清扫术) THW或外源性补充rhTSH 低剂量组(1.1 GBq):217例;
高剂量组(3.7 GBq):217例78 治疗后6~9个月:WBS(−); sTg<2 ng/ml 影像检查(WBS、超声、PET/CT等)提示复发;组织病理学检查结果证实为复发;sTg≥2 ng/ml Schlumberger
等[4]2018 法国 590/162 693/58 T1~3,
N0,
M0TT THW或外源性补充rhTSH 低剂量组(1.1 GBq):363例;
高剂量组(3.7 GBq):363例6~110 治疗后6~10个月:超声(−)且sTg<1 ng/ml;TgAb(+),WBS(−) 组织病理学检查结果证实为复发;影像检查提示复发;sTg>1 ng/ml Fallahi等[5] 2012 伊朗 286/55 326/15 T1~3,
N1~3,
M0TT(大多数伴淋巴结清扫术) THW 低剂量组(1.1 GBq):171例;
高剂量组(3.7 GBq):170例12 治疗后6~12个月:WBS(−);sTg<2 ng/ml WBS(+);sTg>2 ng/ml Kukulska等[7] 2010 波兰 285/24 265/44 T1~3,
N1~3,
M0TT或NTT(大多数伴淋巴结清扫术) THW 低剂量组(1.1 GBq或2.2 GBq):214例;高剂量组(3.7 GBq):95例 24~120 治疗后12个月:WBS(−);sTg<10 ng/ml sTg>1 ng/ml;超声或其他影像检查提示复发 Ma等[8] 2017 中国 199/79 268/7a T1~3,
N1~3,
M0TT 或NTT(伴或不伴淋巴结清扫术) THW 低剂量组(1.85 GBq):155例;高剂量组(3.7 GBq):123例 24~36 治疗后6~9个月:WBS(−);sTg<2 ng/ml 影像检查(WBS、超声等)提示复发;sTg>2 ng/ml Ahtiainen等[9] 2020 芬兰 129/31 146/11b T1~3,
N1~3,
M0TT或NTT THW 低剂量组(1.1 GBq):81例、
高剂量组(3.7 GBq):79例156 治疗后4~8个月:WBS(−);sTg<1 ng/ml 组织病理学检查结果证实为复发;影像检查(WBS、CT、MRI等)提示复发;sTg>1 ng/ml Dong等[10] 2021 中国 363/143 − T1~2,
N0~1,
M0TT或NTT(伴或不伴淋巴结清扫术) THW 低剂量组(1.1 GBq):251例;
高剂量组(3.7 GBq):255 例54 治疗后6~9个月:超声(−)且sTg<1 ng/ml或抑制性Tg<0.2 ng/ml;TgAb(+);WBS(−) 组织病理学检查结果证实为复发;影像检查(超声、CT等)提示复发;sTg>1 ng/ml 注:a表示另有3例为滤泡型甲状腺乳头状癌;b表示另有3例为PTC和FTC均有;−表示无此项数据;PTC为甲状腺乳头状癌;FTC为甲状腺滤泡状癌;TNM为肿瘤、淋巴结、转移;TSH为促甲状腺激素;TT为全切除术;NTT为近全切除术;THW为甲状腺激素戒断;rhTSH为重组人促甲状腺激素;WBS为全身扫描;sTg为刺激性甲状腺球蛋白;PET为正电子发射断层显像术;CT为计算机体层摄影术;TgAb为甲状腺球蛋白抗体;MRI为磁共振成像 表 2 不同剂量131I治疗中低危分化型甲状腺癌后短期疗效的亚组分析
Table 2. Subgroup analysis of short-term efficacy of different doses of 131I in the treatment of low- and intermediate-risk differentiated thyroid cancer
亚组组别 文献序号 RR(95%CI) P值 异质性检验 P值 I2(%) 地区 欧洲 3–4,7,9 0.95(0.90,1.01) 0.08 0.98 0 亚洲 5,8,10 0.86(0.68,1.08) 0.20 <0.0001 92 术式 TT 4–5 0.78(0.49,1.23) 0.28 0.0007 91 NTT 3,7–10 0.97(0.93,1.01) 0.15 0.76 0 危险度分层 中低危 3,5,7–10 0.92(0.83,1.01) 0.08 0.0004 78 低危 4 0.98(0.83,1.14) 0.76 − − TSH刺激方式 THW 5,7–10 0.90(0.79,1.02) 0.11 0.0001 83 THW/外源性补充rhTSH 3–4 0.96(0.90,1.03) 0.23 0.79 0 短期疗效评估标准 Tg<10 ng/ml 7 0.94(0.86,1.03) 0.20 − − Tg<2 ng/ml 3,5,8 0.85(0.68,1.05) 0.13 0.0001 90 Tg<1 ng/ml 4,9 0.96(0.84,1.11) 0.61 0.77 0 注:文献[10]因将短期疗效评估标准Tg分为刺激性Tg<1 ng/ml或抑制性Tg<0.2 ng/ml,故将其剔除。TT为全切除术;NTT为近全切除术;TSH为促甲状腺激素;THW为甲状腺激素戒断;rhTSH为重组人促甲状腺激素;Tg为甲状腺球蛋白;RR为相对危险度;CI为置信区间;−表示无此项数据 表 3 不同剂量131I治疗中低危分化型甲状腺癌后长期预后的亚组分析
Table 3. Subgroup analysis of long-term prognosis after different doses of 131I in the treatment of low- and intermediate-risk differentiated thyroid cancer
亚组组别 文献序号 RR(95%CI) P值 异质性检验 P值 I2(%) 术式 TT 4–5 1.09(0.28,4.21) 0.80 0.21 36 NTT 3,7–10 0.88(0.52,1.50) 0.63 0.87 0 危险度分层 中低危 3,5,7–10 2.00(0.50,7.94) 0.32 − − 低危 4 0.83(0.50,1.37) 0.46 0.89 0 随访时间1 <5 年 5,8,10 0.45(0.10,2.02) 0.30 0.84 0 ≥5年 3–4,7,9 1.03(0.60,1.75) 0.93 0.69 0 随访时间2 <10 年 3–5,7–8,10 1.00(0.56,1.76) 0.99 0.68 0 ≥10年 9 0.80(0.35,1.82) 0.54 − − 注:TT为全切除术;NTT为近全切除术;RR为相对危险度;CI为置信区间;−表示无此项数据 -
[1] 中华医学会核医学分会. 131I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(4): 218−241. DOI: 10.3760/cma.j.cn321828-20201113-00412.
Chinese Society of Nuclear Medicine. Guidelines for radioiodine therapy of differentiated thyroid cancer (2021 edition)[J]. Chin J Nucl Med Mol Imaging, 2021, 41(4): 218−241. DOI: 10.3760/cma.j.cn321828-20201113-00412.[2] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1−133. DOI: 10.1089/thy.2015.0020. [3] Dehbi HM, Mallick U, Wadsley J, et al. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2019, 7(1): 44−51. DOI: 10.1016/S2213-8587(18)30306-1. [4] Schlumberger M, Leboulleux S, Catargi B, et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial[J]. Lancet Diabetes Endocrinol, 2018, 6(8): 618−626. DOI: 10.1016/S2213-8587(18)30113-X. [5] Fallahi B, Beiki D, Takavar A, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial[J]. Nucl Med Commun, 2012, 33(3): 275−282. DOI: 10.1097/MNM.0b013e32834e306a. [6] Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?[J/OL]. Control Clin Trials, 1996, 17(1): 1–12[2023-03-22]. https://www.sciencedirect.com/science/article/abs/pii/0197245695001344?via%3Dihub. DOI: 10.1016/0197-2456(95)00134-4. [7] Kukulska A, Krajewska J, Gawkowska-Suwińska M, et al. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi[J/OL]. Thyroid Res, 2010, 3(1): 9[2023-03-22]. https://thyroidresearchjournal.biomedcentral.com/articles/10.1186/1756-6614-3-9. DOI: 10.1186/1756-6614-3-9. [8] Ma C, Feng F, Wang SY, et al. Chinese data of efficacy of low- and high-dose iodine-131 for the ablation of thyroid remnant[J]. Thyroid, 2017, 27(6): 832−837. DOI: 10.1089/thy.2015.0658. [9] Ahtiainen V, Vaalavirta L, Tenhunen M, et al. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up[J]. Acta Oncol, 2020, 59(9): 1064−1071. DOI: 10.1080/0284186X.2020.1785003. [10] Dong P, Qu Y, Yang L, et al. Outcomes after radioiodine ablation in patients with thyroid cancer: long-term follow-up of a Chinese randomized clinicaltrial[J]. Clin Endocrinol (Oxf), 2021, 95(5): 782−789. DOI: 10.1111/cen.14563. [11] Mäenpää HO, Heikkonen J, Vaalavirta L, et al. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study[J/OL]. PLoS One, 2008, 3(4): e1885[2023-03-22]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001885. DOI: 10.1371/journal.pone.0001885. [12] James DL, Ryan ÉJ, Davey MG, et al. Radioiodine remnant ablation for differentiated thyroid cancer: a systematic review and meta-analysis[J]. JAMA Otolaryngol Head Neck Surg, 2021, 147(6): 544−552. DOI: 10.1001/jamaoto.2021.0288. [13] Song XH, Meng ZW, Jia Q, et al. Different radioiodine dose for remnant thyroid ablation in patients with differentiated thyroid cancer: a meta-analysis[J]. Clin Nucl Med, 2015, 40(10): 774−779. DOI: 10.1097/RLU.0000000000000914. [14] Vardarli I, Weidemann F, Aboukoura M, et al. Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis[J/OL]. BMC Cancer, 2020, 20(1): 550[2023-03-22]. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-020-07029-3. DOI: 10.1186/s12885-020-07029-3. [15] Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J]. N Engl J Med, 2012, 366(18): 1663−1673. DOI: 10.1056/NEJMoa1108586. [16] Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer[J]. N Engl J Med, 2012, 366(18): 1674−1685. DOI: 10.1056/NEJMoa1109589.